Insider · CIK 0001184778
Gary W Pace
Files at CRDF (Cardiff Oncology, Inc.). First filing Nov 14, 2023, latest Jul 16, 2026.
In brief
Gary W Pace files SEC Form 4 as director at CRDF (Cardiff Oncology, Inc.). Since Nov 14, 2023, Gary W Pace has reported 6 open-market buys worth $2.8M and 0 open-market sells worth $0, the latest filed on Jul 16, 2026.
A track record needs three past buys with six months of prices behind them; Gary W Pace has 2, so none is measured yet.
The newest scored trade: bought $1000k of CRDF on Jul 14, 2026, filed Jul 16, 2026, scored 71 (notable). In the last 12 months: 2 buys worth $1.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CRDF: Cardiff Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 71Notable | Cardiff Oncology, Inc. | $1000k 687,285 shares | +51% | +11% from low-71% from high | |
| 47Moderate | Cardiff Oncology, Inc. | $37k 30,000 shares | +2% | +3% from low-73% from high | |
| 60Notable | CRDFbuy Cardiff Oncology, Inc. | $711k 290,000 shares | +27% | +8% from low-53% from high | |
| 64Notable | Cardiff Oncology, Inc. | $940k 361,615 shares | +52% | - | |
| 34Weak | CRDFbuy Cardiff Oncology, Inc. | $41k 30,000 shares | +4% | +42% from low-38% from high | |
| 33Weak | CRDFbuy Cardiff Oncology, Inc. | $22k 22,950 shares | +4% | +4% from low-54% from high |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock | +687,285 | $1.46 | $1000k | 2,043,661 | Jul 16, 2026 |
| Jul 14, 2026 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock Purchase Warrantderivative | +687,285 | $0.00 | $0 | 687,285 | Jul 16, 2026 |
| Jun 18, 2026 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock | +30,000 | $1.22 | $37k | 1,356,376 | Jun 22, 2026 |
| Jun 11, 2026 | CRDF Cardiff Oncology, Inc. | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 228,104 | Jun 15, 2026 |
| Jul 30, 2025 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock | +275,000 | $2.45 | $674k | 1,330,676 | Jul 31, 2025 |
| Jul 30, 2025 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stockindirect: By minor child | +15,000 | $2.45 | $37k | 1,345,676 | Jul 31, 2025 |
| Jun 26, 2025 | CRDF Cardiff Oncology, Inc. | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 187,539 | Jun 27, 2025 |
| Dec 11, 2024 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock | +350,115 | $2.60 | $910k | 1,047,876 | Dec 12, 2024 |
| Dec 11, 2024 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stockindirect: By minor child | +11,500 | $2.60 | $30k | 1,059,376 | Dec 12, 2024 |
| Dec 19, 2023 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock | +30,000 | $1.37 | $41k | 697,761 | Dec 19, 2023 |
| Nov 10, 2023 | CRDF Cardiff Oncology, Inc. | POpen-market purchase Common Stock | +22,950 | $0.98 | $22k | 667,761 | Nov 14, 2023 |
Questions about Gary W Pace
Answered from the filings on this page, as of the latest one.
Is Gary W Pace buying or selling?
In the last 12 months Gary W Pace reported 2 open-market buys worth $1.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $1000k of CRDF on Jul 14, 2026. Grants, option exercises and tax withholding are not counted.
How did Gary W Pace's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gary W Pace has 2.
Where does Gary W Pace file Form 4?
Gary W Pace has filed Form 4 at CRDF (Cardiff Oncology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.